Answers are grounded in this paper and cite their sources.
Insufficient osteoinductive capacity and deficient mesenchymal stem cells (MSCs) remain major challenges for artificial bone materials in treating critical-sized bone defects. To alleviate these limitations, we engineered mesoporous bioactive glass (MBG) nanoparticles with superior osteogenic activity via loading of bone morphogenetic protein-2 (BMP-2) and exceptional MSC recruitment capacity by covalent grafting of nucleic acid aptamer Apt19S. The BMP-2-immobilized MBG (MBG-BMP-2) exhibited sustained release of BMP-2, primarily attributed to the confinement effects of size-matched mesopores. The Apt19S-modified MBG (MBG-Apt19S) effectively recruited bone marrow MSCs (BMSCs) in vitro and efficiently promoted migration of targeted MSCs in vivo. MBG-BMP-2 effectively promoted osteogenic differentiation of BMSCs in vitro and enhanced new bone formation in a rat cranial defect model. In contrast, while MBG-Apt19S showed less direct osteogenic stimulation to BMSCs in vitro, it elicited a substantially greater bone regeneration response in vivo, outperforming even MBG-BMP-2. Notably, MBG co-immobilized with BMP-2 and Apt19S (MBG-BA) produced the most robust osteogenic outcomes. Mechanistically, this superior performance was ascribed to the concurrent activation of the Smad1/5/8 and ERK1/2 signaling axes. This study elucidates the outstanding effects of osteoinductivity and MSC recruitment by MBG-BA, which could offer valuable insights for the development of multifunctional artificial bone materials.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: